No abstract

excellent if £5%. From 2016 to 2019 an audit was carried out annually, selecting a random sample of 30 patients and establishing an annual improvement plan according to the results (Table 1).The improvement proposals established for each year were: 2016, include a week rotation in the reconciliation area for the first-year resident; 2017, extend MR rotation of the thirdyear resident from 2 to 5 months; 2018, establish a supervision/review circuit by the reference pharmacist of the RRs performed.

satisfied the following criteria: for undocumented infection, discontinuation of probabilistic antibiotic therapy at 72 hours of apyrexia; for documented infection, continuation of documented antibiotic therapy, according to the recommendations of the local antibiotic guidelines. Results Ninety infectious episodes were studied. The study population comprised 49 men (54%) and 41 women (46%). Average age was 56 years. Cefepime or piperacillin/tazobactam were systematically introduced as probabilistic therapy. If the infection was undocumented (n=61/90), the duration of probabilistic antibiotic therapy conformed in 41% of cases (n=25/61). For clinical documentation (n=6/90), the conformity rate was 67% (n=4/ 6). For microbiological documentation (n=23/90), compliance rate was 74% (n=17/23). Conclusion and relevance For most undocumented infections, probabilistic antibiotic therapy was prescribed for too long. This may be explained by the fragility of haematology patients and the fear of being confronted with recurrence of infection. For documented infections, conformity was very satisfying, as haematologists have extensive knowledge of infectiology. In order to harmonise prescription duration and continue to prevent the emergence of bacterial resistance, a guide for correct use of antibiotics and a second prospective study should be considered.

psoriasis. Median age was 50.7 years (range 5.9-91.7) and 221 (61.9%) patients were men. 282 patients (79%) were treated with only one biological drug: 75 patients with anti-TNF-a, 132 with anti-IL-17 and 75 with anti-IL-23. 65 patients (18.2%) were treated with two biological drugs in sequence (table 1). Conclusion and relevance More than 97% of patients were treated with only one (79%) or two (18.2%) biological drugs for moderate-to-severe plaque psoriasis, with a prevalence of anti-IL-17. Further investigation of the causes for the change from one to another biological drug is needed. These could include adverse events, ineffectiveness or other reasons.

No abstract